Source: Virtual Congress 2020 – Aspects of acute and chronic airway infections in children
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Asfuroglu (ANKARA, Turkey), T. Ramasli Gursoy (ANKARA, Turkey), Z. Onay (ANKARA, Turkey), T. Sismanlar Eyuboglu (ANKARA, Turkey), E. Sunar Yayla (ANKARA, Turkey), A. Aslan (ANKARA, Turkey), S. Bakkaloglu Ezgu (ANKARA, Turkey), H. Soylemezoglu (ANKARA, Turkey), N. Buyan (ANKARA, Turkey). Risk of tuberculosis in pediatric patients treated with biological agents. 4650

Member's Comments

No comment yet.

Related content which might interest you: Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Treating tuberculosis in patients with comorbidities Source: International Congress 2018 – PG13 Challenges in the treatment of tuberculosis Year: 2018 Risk Factors for tuberculosis in patients on anti-TNF treatment Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Screening and monitoring of tuberculosis in patients on biologics treatment Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Forecasting the risk of medicinal complications from the chemical therapy in patients with multi-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Treatment outcome and risk factors of death in elderly patients diagnosed as new cases of tuberculosis Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Risk factors of hepatotoxicity during tuberculosis treatment and management Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I Year: 2008 Risk factors for fatal tuberculosis among immunocompetent patients. Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015 Risk factors for hospitalisation of CAP patients initially treated in an outpatient setting Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Cardiovascular disease risk in patients with nontuberculous mycobacteria disease treated with macrolide Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Predictive factors of sequelae among Tunisian patients treated for pulmonary tuberculosis. Source: International Congress 2018 – Pulmonary tuberculosis: long term complications, rehabilitation and challenges Year: 2018 Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006 Risk factors for drug-resistant tuberculosis patients in Lithuania, 2002–2008 Source: Eur Respir J 2012; 39: 1266-1269 Year: 2012 Risk factors for rifampicine resistant tuberculosis cases and treatment results with standard regimens Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008